<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03664661</url>
  </required_header>
  <id_info>
    <org_study_id>HenanCH CAR 2-2</org_study_id>
    <nct_id>NCT03664661</nct_id>
  </id_info>
  <brief_title>BCMA-CAR-T in Relapsed/Refractory Multiple Myeloma</brief_title>
  <official_title>a Single-center, One Arm, Open Clinical Study of BCMA Nanobody CAR-T Cell in Refractory/Relapsed Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Pregene (ShenZhen) Biotechnology Company, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Henan Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the safety and efficacy of BCMA nanobody CAR-T cells in relapsed/refractory
      myeloma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are no effective regimens for relapsed/refractory myeloma. BCMA express extensively in
      mature B cells and plasma cells. Myeloma cells express BCMA universally. BCMA signal pathway
      can induce plasma cell proliferation and survival, down-regulation of BCMA could control the
      progression of myeloma. The BCMA CAR used in this study consists of BCMA nanobody, CD8 hinge,
      transmembrane region and 4-1bb co-stimulation domain.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 11, 2018</start_date>
  <completion_date type="Anticipated">April 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 10, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>occurrence of study related adverse events</measure>
    <time_frame>4 weeks</time_frame>
    <description>safety of CAR-T cells</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment response rate</measure>
    <time_frame>3 months and 6 months</time_frame>
    <description>response rate according to IMWG criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>copy number of CAR-T cells</measure>
    <time_frame>one year</time_frame>
    <description>copy number of CAR-T cells</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Relapsed/Refractory Myeloma</condition>
  <arm_group>
    <arm_group_label>experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BCMA nanobody CAR-T cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BCMA nanobody CAR-T cells</intervention_name>
    <description>step 1: Collect 50-100ml of peripheral blood for culture of BCMA nanobody CAR- T cells. step 2. After 72 hours, pretreated with FC regimen, details as follow Cyclophosphamide 600-800mg/m2 for 2 days Fludarabine 25-30mg/m2 for 3 days. step 3: After another 48 hours transfusion the cells back to the patients the numbers of infused CAR T cells are 5x106 /kg for the first 3 patients, 1.5x107 /kg for the second 3 patients and 4.5x107 /kg for the third 3 patients.
After finishing this, another 6 patients will be enrolled for observation of efficacy.</description>
    <arm_group_label>experimental group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 and ≤70 years old and the expected lifetime ＞3 months

               -  Active myeloma according to IMWG criteria, and BCMA positive by
                  immunohistochemistry or flow cytometry

               -  No effective treatment option available

               -  ECOG score 0-2

               -  Sufficient heart, liver, kidney function (heart: no heart disease or coronary
                  heart disease, patient heart function NYHA grade 1-2; liver: TBIL ≤ 3ULN, AST ≤
                  2.5ULN, ALT ≤ 2.5ULN; kidney: Cr≤ 1.25ULN);

               -  smoothly peripheral superficial veins

               -  No other serious diseases that conflict with this protocol (eg, autoimmune
                  diseases, immunodeficiency, organ transplantation)

               -  No history of other malignancies

               -  Women of childbearing age must be negative for blood pregnancy test within 7 days
                  and must take appropriated contraceptive measures during and 3 months after the
                  study

               -  The patient himself agrees to participate in this clinical study and signed the
                  &quot;informed consent&quot;

        Exclusion Criteria:

          -  Severe infectious 4 weeks before enrollment

          -  Active hepatitis B or C viral hepatitis, HIV,

          -  Severe autoimmune disease or immunodeficiency disease

          -  Severe allergies

          -  Severe mental disorder

          -  Patients who used high-dose glucocorticoids within 1 week

          -  Participation in other clinical studies in the past 3 months or having been treated
             with other gene products
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yongping Song, M.D</last_name>
    <role>Study Chair</role>
    <affiliation>Henan Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yongping Song, M.D</last_name>
    <phone>+86-371-65587199</phone>
    <email>songyongping2018@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Quanli Gao, M.D</last_name>
    <phone>+86-15038171966</phone>
    <email>gaoquanli2015@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer Hospital Affiliate to Zhengzhou University &amp; Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongping Song</last_name>
      <phone>+86-13521186987</phone>
      <email>ph200811@163.com</email>
    </contact>
    <investigator>
      <last_name>Yongping Song</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 6, 2018</study_first_submitted>
  <study_first_submitted_qc>September 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2018</study_first_posted>
  <last_update_submitted>September 7, 2018</last_update_submitted>
  <last_update_submitted_qc>September 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

